Shanghai Rendu Biotechnology (stock code: 688193) is a leading high-tech enterprise in China specializing in RNA molecular diagnostic technology and products. Established in 2007, Rendu Biotechnology is dedicated to the development and promotion of RNA molecular diagnostic products based on real-time fluorescence isothermal amplification detection technology (SAT technology). The company possesses a complete set of independent intellectual property rights, encompassing the research, development, and production of diagnostic reagents and fully automated supporting instruments.

With a SAT technology platform boasting 46 authorized patents, Rendu Biotechnology offers 20 NMPA-certified and market-available products. SAT technology, compared to DNA molecular diagnostic technology (PCR), exhibits advantages such as high sensitivity, strong specificity, low cross-contamination, and easy implementation of fully automated high-throughput detection. These molecular diagnostic products, based on SAT technology, find broad applications in various fields such as clinical testing, blood screening, food safety testing, emergency response to infectious diseases, and rapid response.

Visit their website to learn more about Shanghai Rendu Biotechnology and explore their range of cutting-edge products and services